BR112012017071A2 - produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular - Google Patents

produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular

Info

Publication number
BR112012017071A2
BR112012017071A2 BR112012017071A BR112012017071A BR112012017071A2 BR 112012017071 A2 BR112012017071 A2 BR 112012017071A2 BR 112012017071 A BR112012017071 A BR 112012017071A BR 112012017071 A BR112012017071 A BR 112012017071A BR 112012017071 A2 BR112012017071 A2 BR 112012017071A2
Authority
BR
Brazil
Prior art keywords
ocular
pharmaceutical product
vascular permeability
agiogenesis
prevent
Prior art date
Application number
BR112012017071A
Other languages
English (en)
Inventor
Atsushi Nakajima
Chihiro Hibi
Miho Nozaki
Yuchiro Ogura
Original Assignee
Univ Nagoya City
Sanwa Kagaku Kenkyusho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nagoya City, Sanwa Kagaku Kenkyusho Co filed Critical Univ Nagoya City
Publication of BR112012017071A2 publication Critical patent/BR112012017071A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular. trata-se de um produto farmacêutico para prevenir ou tratar um distúrbios acompanhado da angiogênese ocular e/ou do aumento da permeabilidade vascular, ocular, o qual é composto por uma combinação de um agente anti-vegf com um derivado específico da hidantoína representado pela fórmula geral (i) (na qual, x representa um átomo de halogênio ou hidrogênio, e r^ 1^ e r^ 2^ representam, juntos ou á parte, um átomo de hidrogênio ou um grupo alquila c~ 1-6~ opcionalmente substituído), ou um de seus sais aceitáveis do ponto de vista farmacêutico.
BR112012017071A 2010-01-14 2011-01-13 produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular BR112012017071A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010006159 2010-01-14
JP2010055479 2010-03-12
PCT/JP2011/050472 WO2011087066A1 (ja) 2010-01-14 2011-01-13 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬

Publications (1)

Publication Number Publication Date
BR112012017071A2 true BR112012017071A2 (pt) 2016-04-12

Family

ID=44304336

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017071A BR112012017071A2 (pt) 2010-01-14 2011-01-13 produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular

Country Status (14)

Country Link
US (1) US20120301478A1 (pt)
EP (1) EP2524693B1 (pt)
JP (2) JP5212849B2 (pt)
KR (1) KR20120129904A (pt)
CN (1) CN102711756A (pt)
AU (1) AU2011206104A1 (pt)
BR (1) BR112012017071A2 (pt)
CA (1) CA2785970A1 (pt)
DK (1) DK2524693T3 (pt)
ES (1) ES2468827T3 (pt)
MX (1) MX2012007941A (pt)
PL (1) PL2524693T3 (pt)
RU (1) RU2012134639A (pt)
WO (1) WO2011087066A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
US20160137717A1 (en) * 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016311385C1 (en) 2015-08-24 2019-08-22 Glaxosmithkline Intellectual Property (No. 2) Limited Biopharmaceutical compositions
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
JOP20200186A1 (ar) 2018-02-02 2020-07-29 Univ Kyoto دواء للوقاية من أو علاج مرض بصري مرتبط بزيادة تكوين أوعية دموية جديدة داخل العين و/ أو نفاذية الأوعية الدموية داخل العين
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61200991A (ja) 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
JP2997894B2 (ja) 1990-11-07 2000-01-11 株式会社三和化学研究所 循環器系疾患の予防及び治療剤
JP3267698B2 (ja) 1992-10-27 2002-03-18 株式会社三和化学研究所 ヒダントイン誘導体及びその塩並びにこれらを有効成分とするメイラード反応阻害剤
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
JPH07242547A (ja) 1994-03-02 1995-09-19 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性単純網膜症の進行阻止剤乃至治療剤
JP3603129B2 (ja) 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
CA2313390A1 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
CN100398153C (zh) 2000-03-24 2008-07-02 诺瓦提斯公司 抗血管生成药与光敏剂的联合制药用途
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
GEP20063755B (en) * 2001-11-09 2006-02-27 Eyetech Pharmaceuticals Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2005027973A2 (en) 2003-09-23 2005-03-31 Novartis Ag Combinations of a vegf receptor inhibitor with other therapeutic agents
US20080085902A1 (en) 2003-09-23 2008-04-10 Guido Bold Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
EP1719774B1 (en) * 2004-01-30 2012-04-25 Sanwa Kagaku Kenkyusho Co., Ltd. Therapeutic agent for diabetic macular edema
JPWO2005079792A1 (ja) 2004-02-20 2008-09-18 株式会社三和化学研究所 重症糖尿病網膜症の予防又は治療剤
US7354581B2 (en) 2005-02-11 2008-04-08 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
DE602006021156D1 (de) 2005-02-22 2011-05-19 Sanwa Kagaku Kenkyusho Co Mittel zur prävention oder behandlung von herzdysfunktion oder myokardschäden durch ischämie oder ischämie-reperfusion
JP5107053B2 (ja) 2005-12-16 2012-12-26 株式会社三和化学研究所 急性腎不全の予防または治療剤
WO2007087457A2 (en) * 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
WO2007097301A1 (ja) 2006-02-20 2007-08-30 Sanwa Kagaku Kenkyusho Co., Ltd. 脳卒中における脳虚血又は脳虚血再灌流障害の予防又は治療剤
US20100111963A1 (en) * 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
CA2673751C (en) * 2007-01-31 2012-05-08 Sanwa Kagaku Kenkyusho Co., Ltd. Protective agent for retinal nerve or optic nerve
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Also Published As

Publication number Publication date
AU2011206104A1 (en) 2012-07-12
JP5212849B2 (ja) 2013-06-19
DK2524693T3 (da) 2014-08-25
EP2524693A4 (en) 2013-05-22
WO2011087066A1 (ja) 2011-07-21
CN102711756A (zh) 2012-10-03
JPWO2011087066A1 (ja) 2013-05-20
EP2524693A1 (en) 2012-11-21
ES2468827T3 (es) 2014-06-17
EP2524693B1 (en) 2014-05-21
RU2012134639A (ru) 2014-02-20
JP2013049701A (ja) 2013-03-14
PL2524693T3 (pl) 2014-11-28
US20120301478A1 (en) 2012-11-29
KR20120129904A (ko) 2012-11-28
MX2012007941A (es) 2012-09-12
CA2785970A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
BR112012017071A2 (pt) produto farmacêutico para prevenir ou tratar distúrbios acompanhados da agiogênese ocular e/ou do aumento da permeabilidade vascular ocular
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
BR112017017529A2 (pt) derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo
EP4316591A3 (en) Oxysterols and methods of use thereof
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
BR112015010977A2 (pt) derivado de piridina, sal farmaceuticamente aceitável do mesmo ou solvato do mesmo, pró-droga, composição farmacêutica, inibidor do urat1, agente para o tratamento ou prevenção de uma ou mais doenças, e, composto
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
BR112014026493A2 (pt) derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
NZ746825A (en) Oxysterols and methods of use thereof
BR112012004851B8 (pt) uso de um derivado de tiazol
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
NZ721645A (en) Compounds for use as gpr120 agonists
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
BR112014026266A2 (pt) derivado de quinazolidinadiona
BR112015031878A2 (pt) composição farmacêutica
TW201613603A (en) Pharmaceutical preparation
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
MX2016014946A (es) Derivados de carboxamida.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]